<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133470</url>
  </required_header>
  <id_info>
    <org_study_id>07-VIN-029</org_study_id>
    <nct_id>NCT01133470</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to

        1. Compare and evaluate the single dose, crossover, bioequivalence study of Fexofenadine
           HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets and Allegra-D 24 hr tablets.

        2. Monitor the adverse events and ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,
      crossover bioequivalence study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER
      Tablets of Dr. Reddy's and Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals Inc., USA
      in healthy, adult, human subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fexofenadine HCl + Pseudoephedrine HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allegra-D 24 hour ER Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine HCl + Pseudoephedrine HCl</intervention_name>
    <description>Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited</description>
    <arm_group_label>Fexofenadine HCl + Pseudoephedrine HCl</arm_group_label>
    <arm_group_label>Allegra-D 24 hour ER Tablets</arm_group_label>
    <other_name>Allegra-D 24 hour ER Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human subjects aged between 18 and 45 years (including both)

          -  Subjects'weight within the normal range according to normal values for the Body Mass
             Index (18.5 to 24.9kgm2)with minimum of 50 kg weight.

          -  Subjects with normal health as determined by personal medical history clinical
             examination and laboratory examinations within the clinically acceptable normal range.

          -  Subjects having normal 12-lead electrocardiogram (ECG).

          -  Subjects having normal chest X-Ray (P/A view).

          -  Have a negative urine screen for drugs of abuse (including amphetamines,barbiturates,
             benzodiazepines, marijuana, cocaine, and morphine).

          -  Have negative alcohol breath test.

          -  Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

        Subjects will be excluded from the study, if they meet any of the following criteria:

          -  Hypersensitivity to Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride or
             related drugs.

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          -  History or presence of significant alcoholism or drug abuse in the past one year.

          -  History or presence of significant smoking (more than 10 cigarettes or beedi's/day).

          -  History or presence of significant asthma, urticaria or other allergic reactions.

          -  History or presence of significant gastric and/or duodenal ulceration.

          -  History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumour.

          -  History or presence of cancer.

          -  Difficulty with donating blood.

          -  Difficulty in swallowing solids like tablets or capsules.

          -  Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg.

          -  Diastolic blood pressure less than SO mm Hg or more than 90 mm Hg.

          -  Pulse rate less than 50/minute or more than 100/minute.

          -  Oral temperature less than 95°F or more than 98.5°F.

          -  Respiratory rate less than 12/minute or more than 20/minute

          -  SUbjects who have used any prescription medication, within 14 days of period 01 dosing
             or OTC medication within 14 days of period 01 dosing.

          -  Major illness during 3 months before screening.

          -  Participation in a drug research study within past 3 months.

          -  Donation of blood in the past 3 months before screening.

          -  Subjects who have consumed xanthine-containing products (including caffeine,
             theobromines, etc.) within 48 hours prior to period 01 dosing.

          -  Subjects who have consumed food or beverages containing grapefruit or pomelo within 14
             days prior to period 01 dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Dharmesh Domadia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veeda Clinical Research Pvt. Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veeda Clinical Research Pvt. Ltd.,</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan / Senior Director</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

